Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1514 - SPARCL1, a novel prognostic predictive factor for GI malignancies: a meta-analysis (32P)


18 Nov 2017


Poster lunch


Translational Research;  Gastrointestinal Cancers


Hanguang Hu


Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653


W. Cai, H. Hu, W. Ge

Author affiliations

  • Department Of Medical Oncology, 2nd Affiliated Hospital of Zhejiang University University School of Medicine, 310009 - Hangzhou/CN


Abstract 1514


Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is abnormally expressed in gastrointestinal (GI) malignancies. However, the correlation between SPARCL1 expression and the prognosis of patients remains unknown. Therefore, we performed a meta-analysis to investigate the potential value of SPARCL1 as a prognostic predictive marker for GI malignancies.


The PubMed, Embase, EBSCO, CNKI, and Wanfang databases were systematically searched for studies examining SPARCL1 and clinicopathological features, including the prognoses of patients. Hazard ratios (HRs) and odds ratios (ORs) from individual studies were calculated and pooled using a random-effects or fix-effects model. Heterogeneity and publication bias analyses were performed.


Data from 8 studies, including a total of 2,356 patients, were summarized. The expression of SPARCL1 suggested a better prognosis (HR = 0.57, 95% CI: 0.445-0.698, P = 0.000) and was associated with clinicopathological features of GI malignancies, including distant metastasis (OR = 0.44, 95% CI: 0.23-0.85, P = 0.014), lymph node metastasis (OR = 0.56, 95% CI: 0.39–0.81, P = 0.002) and tumor differentiation (OR = 2.21, 95% CI: 1.82–2.69, P = 0.000). Subgroup analyses based on cancer type revealed that the expression of SPARCL1 had no effect on lymph node metastasis in colorectal cancer, and it did not influence tumor differentiation in gastric cancer. (all P > 0.05).


SPARCL1 could be a novel prognostic predictive factor for GI malignancies. The expression of SPARCL1 could influence the clinicopathological features of GI malignancies. Further large-scale studies are essential to confirm SPARCL1’s prognostic predictive value, and more fundamental experimental studies are needed to illustrate the mechanisms.

Clinical trial identification

Legal entity responsible for the study

Hanguang HU




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.